NCT04604210CompletedPhase 2
Symptom-specific TMS Targets for Depression and Anxiety
A Pilot Randomized Trial of Distinct Symptom-specific Targets for Transcranial Magnetic Stimulation in Patients With Depression and Anxiety
Source: ClinicalTrials.gov · Last updated 1 Aug 2024
Brief summary (registry, in English)
This pilot study aims to compare two different treatment targets for transcranial magnetic stimulation, an FDA-approved treatment for major depressive disorder (MDD), in terms of their relative efficacy for depression versus anxiety.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 16 Oct 2020
- Start date
- 3 Feb 2021
- Primary completion date
- 28 Dec 2023
- Lead sponsor
- Brigham and Women's Hospital
- Diseases
- Depression
- NCT number
- NCT04604210
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 40
- From 3 Feb 2021 to the primary completion date, 28 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of:
- Moderate or severe substance use disorder in the past six months as defined by DSM-5 criteria, with the exception of cannabis and nicotine use disorders.
- Dementia, as defined by treating neurologist
- Moderate or severe autism spectrum disorder
- Bipolar disorder
- Schizophrenia spectrum disorders
- Current evidence of:
- Substance-induced mood disorder
- Active psychotic symptoms
- Active suicidal ideation
- Contraindications to rTMS treatment:
- Seizure disorder
- Significantly elevated seizure risk, as determined by clinician assessment
- Presence of metallic objects within the head
- Presence of an implanted neurostimulation device within the head
- Contraindications to MRI
- Severe claustrophobia
- Severe pain/illness exacerbated by lying prone in the scanner
- Presence of non-MRI compatible metal foreign bodies or implants
- Weight in excess of 350 lbs
- Shoulder width in excess of maximum tolerable width for scanner
Who the study is looking for
- Adults age 18 to 65
- Meeting FDA guidelines for clinical TMS (DSM-5 diagnosis of major depressive disorder with at least one failed antidepressant trial)1
- Beck Depression Inventory (BDI) score of 20 or higher
- Beck Anxiety Inventory (BAI) score of 16 or higher
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Brigham & Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
Related publications
- Circuit-targeted modulation of anxiety symptoms in individuals with major depression: A randomized head-to-head TMS trial.Mol Psychiatry · 2026 · PMID 41912790
This page is information, not medical advice. Discuss any trial with your doctor.